Figure 4. Abundance of FCER1A and FCER1G transcripts in whole blood samples of RTS,S vaccinated subjects, acute malaria infection and asthma patients. mRNA expression levels for FCER1A and FCER1G were measured by microarrays in whole blood obtained following RTS,S vaccination (GSE18323), or in patients with acute malaria infection (GSE34404) or asthma (GSE2475). GSE18323: Samples were collected at study entry, the day of third vaccination (Day 0), 24 (Day 1) and 72 (Day 3) hours post the third vaccination and two weeks (Day14) post the third vaccination. Of 39 vaccine recipients, 13 were protected (blue) and 26 were not protected (orange) 15 . https://www.ncbi. nlm.nih.gov/geo/query/acc.cgi?acc=GSE18323. GSE34404: Whole blood gene expression profiles and genotypes from 155 West-African children including 94 cases (Rapid Diagnostic (RD) Positive) undergoing the symptomatic phase of blood-stage P. falciparum infection and 61 age-matched controls (RD negative) 34 . https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE34404. GSE24745: Asthmatic subjects (20–60 years of age, with stable, mild allergic asthma, n=17) underwent allergen inhalation challenges. All subjects had an early asthmatic response of ≥ 20% fall in FEV1; most had a late phase response of ≥ 15% fall in FEV1. Blood was collected immediately prior to, and two hours after allergen challenge 35 .